News
CLRB
0.4100
-6.80%
-0.0299
10 Best Biotech Penny Stocks To Buy Now
In this article, we discuss the 10 best biotech penny stocks to buy now. If you want to skip our detailed analysis of the biotech sector, go directly to 5 Best Biotech Penny Stocks To Buy Now. Like all sectors of the economy right now, the biotech sector i...
Insider Monkey · 06/20 13:22
Recap: Cellectar Biosciences Q1 Earnings
Cellectar Biosciences (NASDAQ:CLRB) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Cellectar Biosciences reported in-line EPS of $-0.1 versus an estimate of $-0.1.
Benzinga · 05/10 14:53
BRIEF-Cellectar Reports Financial Results For First Quarter 2022
reuters.com · 05/10 12:57
Cellectar Biosciences GAAP EPS of -$0.10 in-line
Cellectar Biosciences press release (NASDAQ:CLRB): Q1 GAAP EPS of -$0.10 in-line. As of March 31, 2022, the company had cash and cash equivalents of $30.6 million, compared to $35.7 million
Seekingalpha · 05/10 12:52
Cellectar says committee recommends continuing trial of iopofosine in Waldenstrom’s patients
Cellectar Biosciences (NASDAQ:CLRB) on Tuesday said an independent committee recommended that the company continue its phase 2b study of its cancer therapy iopofosine to treat Waldenstrom’s macroglobulinemia (WM), a rare
Seekingalpha · 04/26 13:16
Cellectar Biosciences Announces DMC Review Of Pivotal Trial Of Iopofosine In Waldenstrom's Macroglobulinemia
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced
Benzinga · 04/26 12:12
BRIEF-Cellectar Biosciences Reports Positive DMC Review of Trial of Iopofosine
reuters.com · 04/26 12:09
Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia
Unanimous Agreement on Successful Achievement of Futility/Efficacy AssessmentFLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, develo...
GlobeNewswire · 04/26 12:00
51 Biggest Movers From Thursday
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.
Benzinga · 04/18 09:21
Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 03/23 22:35
Here's Why Cellectar Biosciences Shares Are Rising
Cellectar Biosciences Inc (NASDAQ: CLRB) shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earnings by 10.0%, reporting an EPS loss of 9 cents versus...
Benzinga · 03/21 17:30
BRIEF-Cellectar Reports Financial Results For Year Ended December 2021 And Provides A Corporate Update
reuters.com · 03/21 13:10
Recap: Cellectar Biosciences Q4 Earnings
  Cellectar Biosciences (NASDAQ:CLRB) reported its Q4 earnings results on Monday, March 21, 2022 at 08:30 AM. Here's what investors need to know about the announcement.
Benzinga · 03/21 12:48
Cellectar Biosciences GAAP EPS of -$0.43 beats by $0.01
Cellectar Biosciences press release (NASDAQ:CLRB): FY GAAP EPS of -$0.43 beats by $0.01. As of December 31, 2021, the company had cash and cash equivalents of $35.7 million, compared to $57.2
Seekingalpha · 03/21 12:39
Cellectar to Participate at Upcoming Banking Conferences
FLORHAM PARK, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today anno...
GlobeNewswire · 03/10 21:05
Sector Update: Health Care
MT Newswires · 02/24 13:13
Femasys Names Dov Elefant as CFO
MT Newswires · 02/24 12:07
Cellectar Biosciences appoints Chad Kolean as CFO, Jarrod Longcor as COO
Cellectar Biosciences (NASDAQ:CLRB) names Mr. Chad Kolean as Chief Financial Officer and promoted Mr. Jarrod Longcor to the role of Chief Operating Officer.  Mr. Kolean, a seasoned thirty-year industry veteran, will replace Dov Elefant, who
Seekingalpha · 02/23 13:44
BRIEF-Cellectar Biosciences Inc Says Chad Kolean Has Been Appointed Chief Financial Officer
reuters.com · 02/23 13:14
Cellectar Biosciences Announces Executive Leadership Changes
Names Mr. Chad Kolean as Chief Financial Officer Promotes Mr. Jarrod Longcor to Chief Operating Officer FLORHAM PARK, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focuse...
GlobeNewswire · 02/23 13:00
More
Webull provides a variety of real-time CLRB stock news. You can receive the latest news about Cellectar Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About CLRB
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.